Aspirin is the latest drug set to be evaluated in the large-scale Recovery trial — the Oxford University-run study that discovered the use of the common corticosteroid medicine dexamethasone in treating COVID-19 cases. According to a press release published today, aspirin’s blood-thinning properties could help avoid complications from blood clots associated with COVID-19.The everyday medicine joins a slate of more advanced treatments, like Regeneron’s monoclonal antibodies, that have come under the scrutiny of scientists in the U.K. as potential treatments for coronavirus infections. Oxford University’s Peter Horby, co-chief investigator of the Recovery trial, said the fact the medicine is safe, inexpensive and widely available added to its appeal. “We are looking for medicines for COVID-19 that can be used immediately by anyone, anywhere in the world,” he said. “We do not know if aspirin is such a medicine but we will find out.”The study will primarily look at patient mortality after 28 days while also assessing hospital stay duration and the need for ventilation. According to the release published by the trial organizers, it’s expected that at least 2,000 infected patients will receive aspirin together with usual care. It will probably take a number of months before the trial produces enough data to judge if aspirin has benefit for patients. Meanwhile, on Thursday, trial organizers said that an independent data monitoring had reviewed evidence associated with Regeneron’s antibody cocktail and concluded that there’s no need to modify the trial. The review was sparked by an announcement from Regeneron of a pause in patient recruitment in a separate study. This article is part of POLITICO’s premium policy service: Pro HealthCare. From drug pricing, EMA, vaccines, pharma and more, our specialized journalists keep you on top of the topics driving the health care policy agenda. Email [email protected] for a complimentary trial.